Physician profile
British Bates
NPI 1396102521
$3,399.31
in general payments reported to CMS, 2019-2025
50 companies · $618 in 2025
The $618 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $192 · 2023: $822 · 2024: $1,390 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $481.61 | 2021-2025 | |
| Abbvie INC. | $217.67 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $203.13 | 2024-2025 | Libtayo |
| Boston Scientific Corporation | $136.93 | 2021-2025 | Wavewriter Alpha Prime 16, General - Therapies |
| Incyte Corporation | $126.73 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Abbott Laboratories | $96.95 | 2021-2024 | Proclaim, Axium |
| Tersera Therapeutics LLC | $93.80 | 2023-2024 | Zoladex, Xermelo |
| Exelixis INC. | $86.21 | 2023-2025 | Cabometyx |
| Taiho Oncology, INC. | $84.81 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $83.26 | 2022-2024 | Calquence |
| Lilly USA, LLC | $79.96 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmaessentia USA Corporation | $77.46 | 2023-2024 | Besremi |
| Merck Sharp & Dohme LLC | $76.32 | 2023-2024 | Lynparza, Keytruda, Reblozyl |
| Karyopharm Therapeutics INC. | $69.88 | 2023-2024 | Xpovio |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw British Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.